# Dose Painting With the Gamma Knife Lightning Dose Optimizer: Technical Description and Validation of Dose Delivery

Andrew B. Barbour, MD, PhD;\* Evan Gates, PhD; Eric Ford, PhD; Mark Phillips, PhD; Lia M. Halasz, MD

# Abstract

**Objective:** The recently introduced Gamma Knife (GK) Lightning (Elekta) fast inverse planning dose optimizer allows concurrent optimization of multiple targets, but the optimizer's use for generating a simultaneous integrated boost (SIB) plan has not been described and validated for accuracy of dose delivery. Here, we describe a method for creating an SIB using the GK Lightning optimizer and conduct validation of dose delivery.

**Materials and Methods:** Radiochromic film was positioned in an anthropomorphic phantom. A 15.7-cm<sup>3</sup> irregular contour was drawn to represent a brain metastasis resection cavity, a uniform 2-mm radial-expansion contour created, and a 1.6-cm<sup>3</sup> contour drawn representing a nodule of residual disease within the cavity. Targets were prescribed 3 Gy (2-mm expansion), 4 Gy (cavity), and 5 Gy (residual disease) in 1 fraction. Within the GammaPlan Lightning optimizer, "beam-on time" and "low-dose" settings were iteratively adjusted to create a clinically acceptable plan. Treatment was delivered using the GK Icon system. The film was scanned and calibrated for absolute dosimetry. Global gamma index analyses were performed at various dose and distance tolerances.

**Results:** An 18-minute treatment plan with 40 shots was delivered. Prescription isodose lines were 3 Gy at 55% (2-mm expansion), 4 Gy at 69% (resection cavity), and 5 Gy at 75% (residual disease). All target volumes had greater than or equal to 99% prescription dose coverage and the maximum dose was 6.9 Gy. Paddick conformality indices were 0.79 (2-mm expansion), 0.74 (resection cavity), and 0.15 (residual disease). Gamma index pass rate, mean, and median values were 77%, 0.68, and 0.54 at 1%/1-mm tolerance, 85%, 0.58, and 0.49 at 2%/1-mm tolerance, and 97%, 0.34, and 0.28 at 2%/2-mm tolerance.

**Conclusion:** We successfully created an SIB plan with the GK Lightning optimizer, verifying dose delivery within clinically acceptable tolerances. Future work is needed to determine optimal dose levels for use in clinical practice and determine what disease entities may benefit from an SIB.

Keywords: stereotactic radiosurgery, stereotactic radiation therapy, simultaneous integrated boost, SIB, fast inverse planning

Affiliations: Department of Radiation Oncology, University of Washington - Fred Hutchinson Cancer Center, Seattle.

**Corresponding author:** \*Andrew B. Barbour, MD, PhD, Department of Radiation Oncology, University of Washington – Fred Hutchinson Cancer Center, 1959 NE Pacific St, Box 356043, Seattle, WA. (barboura@uw.edu)

**Disclosures:** ABB, MP: no conflicts of interest. EF: leadership role on ASTRO board of directors. EG: employed by Varian Medical Systems after data collection and analysis were performed for this work. LMH: grants or contracts from BioMimetix. Abstract presented at 2024 Radiosurgery Society annual meeting in Chicago, Illinois. Citation: Barbour AB, Gates E, Ford E, Phillips M, Halasz LM. Dose painting with the Gamma Knife Lightning dose optimizer: an updated technique for delivering an intracranial simultaneous integrated boost. 2024. RSS Annual Meeting, Chicago, IL.

Data sharing statement: The source data is available upon reasonable request to the corresponding author.

Published: June 1, 2024. https://doi.org/10.1016/10.37549/ARO-D-24-00012

@Anderson Publishing, Ltd. All rights reserved. Reproduction in whole or part without express written permission is strictly prohibited.

#### Introduction

Postoperative radiation therapy is strongly recommended for patients with resected brain metastases (BM).<sup>1</sup> Radiographic evidence of residual or recurrent disease is detected in 4% to 13% of patients with resected BM, including in 5% of patients following gross total resection.<sup>2-5</sup> Such patients may benefit from a simultaneous integrated boost (SIB) to areas of gross disease to improve local control,<sup>6</sup> while respecting brain dose-volume tolerances for radiosurgery.

As previous versions of the Gamma Knife (GK) (Elekta) treatment planning system did not explicitly allow for an SIB, Grossberg et al7 described 2 methods of dose painting an SIB. These planning techniques rely on manual forward planning of nested targets, require significant user expertise, are limited to 2 dose levels, do not allow concurrent calculation of dosimetric coverage statistics for the nested treatment volumes, and have not undergone quality assurance for dose delivery validation. Validation of accurate dose delivery is particularly important given the complexity of overlapping dose calculation matrices.8-10

Recently, a fast inverse planning (FIP) dose optimizer (Lightning) was introduced for GK, allowing concurrent optimization of multiple targets while incorporating organsat-risk (OAR) dose constraints.<sup>11</sup> This FIP optimizer demonstrated the potential to improve treatment planning quality and efficiency for a variety of clinical scenarios, showing particular utility when treating irregularly shaped targets.<sup>12-15</sup> Here, we describe the use of the Lightning FIP optimizer for dose painting in GK radiosurgery, using the example of residual or recurrent tumor at the time of adjuvant radiation therapy

for a resected BM, and we conduct quality assurance of dose delivery. To demonstrate the accessibility and flexibility of this SIB technique, we extend the 2-target example of Grossberg et al<sup>7</sup> (resection cavity and gross tumor) by adding a third nested target consisting of a resection cavity radial margin.<sup>16</sup>

#### **Materials and Methods**

## Technical Description of Dose Painting Technique

Standard GK techniques are used for patient setup, image coregistration, and target contouring. At least 2 nested target volumes are created consisting of the resection cavity and/or a radial expansion to a resection cavity margin, plus a volume capturing recurrent or residual gross tumor. Overlapping dose calculation matrices are placed for the nested targets. A prescription dose (in Gy) is specified for each target volume. If desired, a maximum dose can be specified and the option of "full coverage" can be selected to increase target coverage from the default of greater than or equal to 95% to greater than or equal to 99%. The OAR dose constraints can be specified but are not required. An initial plan is then optimized, typically using the default "low dose" (LD) and "beam-on time" (BOT) penalty settings of 0.50 (range, 0.00-1.00).

The initial plan is reviewed for metrics such as target coverage, total treatment time, Paddick conformity index (PCI), gradient index (GI), normal tissue dosimetry, and isodose. While the Lightning FIP does not allow the user to prescribe a specific isodose, the optimized isodose can be manipulated in subsequent iterations by changing the LD and BOT penalty settings, toggling the option of "full coverage," and/or providing values for "maximum dose." Treatment plan optimization is iterated under a variety of settings until a clinically acceptable plan is developed, at which point treatment delivery follows standard GK techniques.

#### Quality Assurance of Dose Delivery

To conduct quality assurance of this technique, we created a clinically representative treatment plan for an anthropomorphic phantom. Using a CT simulation scan of the phantom, a 15.7cm3 irregular contour was drawn to represent a brain metastasis resection cavity of a recently treated patient. A 2-mm uniform radial expansion was created for an additional contour (25.5 cm<sup>3</sup>). A 1.6-cm<sup>3</sup> contour was drawn within the resection cavity to represent a gross tumor nodule. In GammaPlan software v11.3.1, overlapping dose matrices were placed using default positions (Figure 1). The 3 targets were prescribed 3 Gy (2-mm expansion), 4 Gy (resection cavity), and 5 Gy (gross tumor) in a single fraction. Prescription doses were selected to match the radiochromic film's optimal dose range, while approximating fractional doses used in 5-fraction treatments. Within the FIP optimizer, "full coverage" was selected, no maximum dose or OAR constraints were specified, and LD and BOT penalty settings were iteratively adjusted to create a clinically acceptable plan. On the GK Icon system, a custom occipital mold was made, an unexposed film (Gafchromic RTQA2) placed in the axial plane of the phantom's cranium, cone-beam CT (CBCT) co-registration conducted, and treatment delivered. The film was scanned (Epson Expression 11000XL) and calibrated for absolute dosimetry using a calibration curve generated from a 6-MV linear

**Figure 1.** Axial (A), coronal (B), and sagittal (C) views of a simultaneous integrated boost Gamma Knife treatment plan for an anthropomorphic phantom with 3 nested target contours (red = 2-mm margin, orange = resection cavity, green = gross tumor). Three overlapping dose calculation matrices are shown by green boxes (alternating dotted and solid lines). Radiochromic film is visualized as a white streak and is localized by the red reticule. The 4 Gy isodose line (yellow contour) results from the 27 shots planned to the resection cavity target and does not represent the composite 4 Gy isodose line of the total 40-shot plan (**Figure 2A**).



accelerator. Corrections were not made for dose delivered by CBCT.<sup>17</sup> To evaluate treatment accuracy, global gamma index analyses were performed at various dose and distance tolerances, excluding points below 30% of the maximum dose. The passing rate was defined as the percentage of points with gamma index less than 1. Film dosimetry and analysis were performed using Radiochromic.com software v4.0.<sup>18</sup>

### **Results**

Using LD and BOT penalty settings of 0.60 and 0.90, respectively, an 18-minute treatment plan with 40 shots was created after 221 seconds of optimization. The plan included 7 shots to the 2-mm margin (2.01 min of BOT), 27 to the resection cavity (12.63 min), and 6 to gross tumor (3.14 min) (Figure 3). Prescription isodose lines were 3 Gy at 55% (2-mm expansion), 4 Gy at 69% (resection cavity), and 5 Gy at 75% (gross tumor) (Figure 2A). All target volumes had greater than or equal to 99% prescription dose coverage and the maximum dose was 7.0

Gy. Mean doses were 4.8 Gy (2-mm expansion), 5.2 Gy (resection cavity), and 6.1 Gy (gross tumor). PCI values were 0.79 (2-mm expansion), 0.74 (resection cavity), and 0.15 (gross tumor). GI was only available for the resection cavity (value = 2.5). On absolute dosimetry with Gafchromic film, the measured maximum dose was 7.112 Gy, 1.6% higher than planned. Gamma index pass rate, mean, and median values were 77%, 0.68, and 0.54 at 1%/1-mm tolerance, 85%, 0.58, and 0.49 at 2%/1-mm tolerance, and 97%, 0.34, and 0.28 at 2%/2-mm tolerance (Figure 2). An average of 17,883 points were evaluated per gamma index analysis.

### **Discussion**

We demonstrated a method for conducting an SIB using the GK Lightning optimizer and validated dose delivery within acceptable clinical thresholds.<sup>8,19</sup> This method allows for concurrent optimization of multiple nested dose volumes, provides dosimetric statistics for each volume, and does not require significant user experience. Additionally, this technique can be applied to concurrently treat multiple brain lesions with an SIB. However, as the GammaPlan user interface is not optimized for SIB planning, this method may be prone to interpretive error. This is exemplified by the nonintuitive interpretation of individual isodose lines when looking at a single target volume (Figures 1, 3), as well as the lack of a color gradient for prescription isodose lines within a composite treatment plan (Figure 2A). Additionally, since shots are delivered sequentially on a target-by-target basis (Figure 3), and the total dose delivered to a given voxel is the summation of dose sequentially delivered to multiple targets (Figure 2A), this method may result in heterogeneous dose rate variability with an undetermined radiobiological significance and be more sensitive to intrafraction positioning errors.<sup>20</sup>

Clinically, our demonstration used the example of recurrent or residual tumor at the time of adjuvant radiation therapy for BM. This work does not address the optimal number of nested treatment volumes, the necessity of treating a radial **Figure 2.** Axial view of simultaneous integrated boost Gamma Knife (Elekta) treatment plan for an anthropomorphic phantom (A) showing 3 target contours (red = 2-mm margin, orange = resection cavity, green = gross tumor) and isodose lines of 3 prescription doses (yellow contours: 3 Gy, 4 Gy, and 5 Gy). Radiochromic film of the delivered treatment plan calibrated for absolute dosimetry (B) with isodose lines of 3 prescription doses (red = 3 Gy, yellow = 4 Gy, green = 5 Gy) and color-scale legend of absolute dose (Gy). Gamma index analyses of radiochromic film at 1%/1-mm (C) and 2%/2-mm (D) tolerances with color-scale legend showing gamma index values (values <1 represent a passing score for a given point).



margin, nor does this work define the most appropriate dose levels or fractionation pattern.<sup>21-24</sup> For the treatment of BM, it is not well defined if an SIB improves outcomes or reduces toxicity, but this SIB method allows for standardization of treatment technique in future clinical trials designed to improve the therapeutic ratio of adjuvant stereotactic radiation therapy.<sup>25</sup> The application of this SIB technique is not limited to adjuvant BM therapy as it could be used to deliver internal boosts to primary brain tumors via lattice radiation therapy.<sup>26,27</sup> Prospective work is needed to optimize the clinical application of this technique to elucidate appropriate clinical indications and dose levels.

#### **Conclusions**

We successfully created an SIB plan with the GK Lightning optimizer and verified dose delivery within clinically acceptable tolerances. Future work is needed to determine optimal dose levels for use in clinical practice and what disease entities may benefit from an intracranial SIB. **Figure 3.** Axial, coronal, and sagittal views (arranged from left to right) of Gamma Knife (Elekta) shot position for the gross tumor (A), resection cavity (B), and 2-mm expansion (C) target volumes. The yellow contour represents the prescription isodose line for each target (2-mm expansion = 3 Gy, resection cavity = 4 Gy, gross tumor = 5 Gy) resulting from the contribution of shots planned to the given target, as opposed to the total 40-shot plan (**Figure 2A**).



#### References

1) Gondi V, Bauman G, Bradfield L, et al. Radiation therapy for brain metastases: an ASTRO clinical practice guideline. *Pract Radiat Oncol.* 2022;12(4):265-282. doi: 10.1016/j.prro.2022.02.003 2) Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. *Neurosurgery*. 2005;56(5):1021-1034. 3) Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. *Neurosurgery.* 1998;42(5):1044-1055. doi:10. 1097/00006123-199805000-00054

4) Tan T-C, McL Black P. Image-guided craniotomy for cerebral metastases: techniques and outcomes. *Neurosurgery*. 2003;53(1):82-89. doi:10.1227/01.neu. 0000068729.37362.f9

5) Benveniste RJ, Ferraro N, Tsimpas A. Yield and utility of routine postoperative imaging after resection of brain metastases. *J Neurooncol.* 2014;118(2):363-367. doi:10.1007/ s11060-014-1440-3

6) Galvin JM, De Neve W. Intensity modulating and other radiation therapy devices for dose painting. *J Clin Oncol.* 2007;25(8):924-930. doi:10.1200/JCO.2007.10.
6716

7) Grossberg A, Zhao Z, Walker G, et al. Dose painting with Gamma Knife: two techniques for delivering different doses to areas of recurrent or residual tumor after resection of brain metastases. *Pract Radiat Oncol.* 2015;5(6):390-397. doi:10.1016/j.prro.2015.08. 001

8) Gopishankar N, Watanabe Y, Subbiah V. MRI-based polymer GEL dosimetry for validating plans with multiple matrices in Gamma Knife stereotactic radiosurgery. *J Appl Clin Med Phys.* 2011;12(2):3333. doi:10. 1120/jacmp.v12i2.3333

9) Platoni K, Grandjean P, Kouloulias V, Patatoukas G, Lefkopoulos D. The impact of dose matrix and voxel dimensions to dose calculation for stereotactic radiosurgery. *J BUON*. 2017;22(5):1307-1313.

10) Douglas JG, Goodkin R. A simple treatment planning strategy for patients with multiple metastases treated with Gamma Knife surgery. *J Neurosurg.* 2006;105 Suppl:2-4. doi:10.3171/sup.2006.105.7.2

11) Sjölund J, Riad S, Hennix M, Nordström H. A linear programming approach to inverse planning in Gamma Knife radiosurgery. *Med Phys.* 2019;46(4):1533-1544. doi:10.1002/mp.13440

12) Wieczorek DJ, Kotecha R, Hall MD, et al. Systematic evaluation and plan quality assessment of the Leksell(R) Gamma Knife(R) lightning dose optimizer. *Med Dosim.* 2022;47(1):70-78. doi:10.1016/j. meddos.2021.08.006 13) Cui T, Nie K, Zhu J, et al. Clinical evaluation of the inverse planning system utilized in Gamma Knife lightning. *Front Oncol.* 2022;12:832656. doi:10.3389/fonc.2022. 832656

14) Spaniol M, Mai S, Zakrzewski T, Ehmann M, Stieler F. Inverse planning in Gamma Knife radiosurgery: a comparative planning study. *Phys Med.* 2021;82:269-278. doi:10. 1016/j.ejmp.2021.02.019

15) Pokhrel D, Bernard ME, Knight J, St Clair W, Fraser JF. Clinical validation of novel lightning dose optimizer for Gamma Knife radiosurgery of irregularshaped arteriovenous malformations and pituitary adenomas. J Appl Clin Med Phys. 2022;23(8):e13669. doi:10.1002/acm2.13669

16) Minniti G, Niyazi M, Andratschke N, et al. Current status and recent advances in resection cavity irradiation of brain metastases. *Radiat Oncol.* 2021;16(1):73. doi: 10.1186/s13014-021-01802-9

17) Alaei P, Spezi E. Imaging dose from cone beam computed tomography in radiation therapy. *Phys Med.* 2015;31(7):647-658. doi:10. 1016/j.ejmp.2015.06.003

18) Méndez I, Rovira-Escutia JJ, Casar B. A protocol for accurate radiochromic film dosimetry using radiochromic.com. *Radiol Oncol.* 2021;55(3):369-378. doi:10.2478/raon-2021-0034

19) Park JM, Kim JI, Park SY, Oh DH, Kim ST. Reliability of the gamma index analysis as a verification method of volumetric modulated arc therapy plans. *Radiat Oncol.* 2018;13(1):175. doi:10.1186/s13014-018-1123-x

20) Ma L, Lee L, Barani I, et al. Shot sequencing based on biological equivalent dose considerations for multiple isocenter Gamma Knife radiosurgery. *Phys Med Biol.* 2011;56(22):7247-7256. doi:10.1088/0031-9155/ 56/22/015

21) Gutschenritter T, Venur VA, Combs SE, et al. The judicious use of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy in the management of large brain metastases. *Cancers (Basel)*. 2020;13(1):70. doi:10.3390/cancers13010070 22) Loftus JP, Shepard M, Liang Y, et al. A comparison of single fraction and multi fraction radiosurgery on the Gamma Knife ICON: a single institution review. *Adv Radiat Oncol.* 2023;8(2):101161. doi:10.1016/j. adro.2022.101161

23) Redmond KJ, De Salles AAF, Fariselli L, et al. Stereotactic radiosurgery for postoperative metastatic surgical cavities: a critical review and International Stereotactic Radiosurgery Society (ISRS) practice guidelines. *Int J Radiat Oncol Biol Phys.* 2021;111(1):68-80. doi:10.1016/j.ijrobp.2021. 04.016

24) Soliman H, Ruschin M, Angelov L, et al. Consensus contouring guidelines for postoperative completely resected cavity stereotactic radiosurgery for brain metastases. *Int J Radiat Oncol Biol Phys.* 2018;100(2):436-442. doi:10.1016/j. ijrobp.2017.09.047

25) Milano MT, Soltys SG, Marks LB, et al. The art of radiation therapy: the necessary risk of radiation necrosis for durable control of brain metastases. *Int J Radiat Oncol Biol Phys.* 2023;115(2):294-296. doi:10.1016/j. ijrobp.2022.07.036

26) Ma L, Kwok Y, Chin LS, Simard JM, Regine WF. Concomitant GRID boost for Gamma Knife radiosurgery. *Med Phys*. 2005;32(11):3419-3423. doi:10.1118/1.2068887

27) Spałek MJ. Lattice radiotherapy: Hype or hope? *Ann Palliat Med.* 2022;11(11):3378-3381. doi:10.21037/apm-22-1081

6